Diagnosis of celiac disease and applicability of ESPGHAN guidelines in Mediterranean countries: a real life prospective study

Andrea Smarrazzo 1,2, Zrinjka Misak 3, Stefano Costa 4, Dušanka Mičetić-Turk 5, Mona Abu-Zekry 6, Aydan Kansu 7, Abdelhak Abkari 8, Karim Bouziane-Nedjadi 9, Mongi Ben Hariz 10, Elefteria Roma 11, Virtut Velmishi 12, Maria Legarda Tamara 13, Thomas Attard 14, Veselinka Djurisic 15, Luigi Greco 1,2 and Giuseppe Magazzù 4*

Abstract
Background: We assessed how the diagnosis of Celiac Disease (CD) is made and how the new ESPGHAN guidelines can be applied in children from countries with different resources.

Methods: A real life prospective study was performed in 14 centres of 13 different Mediterranean countries. Participants were asked to apply the usual diagnostic work-up for CD according to their diagnostic facilities.

Results: There were 1974 patients enrolled in the study, mean age 4 years, 10 months; 865 male, 1109 female. CD was confirmed in 511 (25.9%) and was unconfirmed in 1391 (70.5%) patients; 14 patients were diagnosed as having CD according to the new ESPGHAN guidelines, 43 patients were classified as having potential CD. In all participating countries the diagnosis of CD relied on histology of duodenal biopsy; in 5 countries, HLA, and in one country endomysial antibodies (EMA) were not available. Symptoms did not add a significant increase to the pre-test probability of serological tests. The positive predictive value of tissue transglutaminase type 2 (tTG) antibodies performed with different kits but all corresponding to those recommended by ESPGHAN was 96.1% (95% CI 94–97.9%) in presence of tTG > 10xULN. In 135 patients with tTG > 10xULN, HLA genotyping was performed and in all it was compatible with CD.

Conclusions: The results of our study show that CD diagnosis still relies on intestinal biopsy in the Mediterranean area. New ESPGHAN criteria are not applicable in 5 countries due to lack of resources needed to perform HLA genotyping and, in one country, EMA assay. Further simplification of the new ESPGHAN guidelines might be made according to what preliminarily the present results suggest if confirmed by new prospective studies.

Keywords: Celiac disease, Diagnosis, Mediterranean area, ESPGHAN

Background
Prevalence of celiac disease (CD) has been estimated at around 1% in Western populations [1] but most patients remain undiagnosed. The burden of unrecognized CD in countries with poor resources and facilities for diagnosis is very heavy [2]. Factors influencing the onset of this non communicable epidemics have been taken into consideration also recently [3–8]. New ESPGHAN guidelines [9] state that the protocol for the diagnosis of CD changed as a result of the availability of CD-specific tissue transglutaminase type 2 antibodies (tTG). As in children and adolescents with signs or symptoms suggestive of CD and high tTG titers with levels > 10 times Upper Limits of Normal (ULN), the likelihood of villous atrophy (Marsh type 3) is very high, it has been suggested [9] that histological assessment may be omitted in symptomatic patients in whom these high tTG levels are verified by endomysial antibodies (EMA) positivity and are HLA-DQ2 and/or HLA-DQ8 heterodimer positive.

However ESPGHAN states that it is necessary to perform prospective research studies.
After the publication of the new ESPGHAN criteria, apart from a large study investigating antibody diagnostics in paediatric CD [10], 2 prospective studies [11, 12] have been performed to our knowledge. One other prospective study adopted criteria other than those suggested by the guidelines [13].

Two main problems should be highlighted:

- there are many different tTG antibody tests;
- new ESPGHAN criteria were applied in some studies, but these studies have been performed, with only one exception [12], in tertiary centres of affluent countries in subjects with classical gastrointestinal disease.

Therefore, the conclusions of a recent commentary on the applicability of the new ESPGHAN Guidelines for diagnosing CD in children from resource limited countries [14] rely on a single centre prospective study comprising only 142 children.

The Mediterranean Network for the Management of Food-Induced Diseases (MEDICEL) is a EUROMED-based action in which Mediterranean countries with different resources and diagnostic facilities participate. It, therefore, represents the real life ideal setting in which the new ESPGHAN guidelines can be prospectively applied.

The objectives of this prospective study were to assess how the diagnosis of CD is made in different countries and how the new ESPGHAN guidelines can be applied in different Mediterranean countries.

**Methods**

**Study design**

A real life prospective study was performed in 14 centres of 13 different Mediterranean countries participating to the MEDICEL network; all unselected new cases referred to these Centres for suspected CD and asymptomatic subjects with autoimmune CD-associated diseases or familiarity for CD were enrolled, from April 2013 to July 2014.

Participants were asked to apply the usual diagnostic work-up for CD according to their diagnostic facilities and to classify enrolled subjects as confirmed or unconfirmed CD according to shared criteria, as done in their usual clinical practice. Two sessions of shared agreement on diagnostic criteria were run through the MEDICEL network before starting the study.

Criteria for admission were: age below 18 years, clinical signs and symptoms of CD (systemic, gastrointestinal, extraintestinal) and/or associated autoimmune diseases (type 1 diabetes mellitus, thyroiditis, other autoimmune diseases) and/or no symptoms but familiarity for CD (1st and 2nd degree).

Criteria for exclusion were: already known diagnoses of CD only.

Familiarity, associated diseases, clinical symptoms, tTG as N x Upper Limit Normal (ULN), EMA, histology (Marsh-Oberhuber classification) [15], were collected into the database.

HLA-DQ2/DQ8 and follow-up were performed to confirm uncertain cases.

**Diagnostic procedures**

The tTG, EMA and HLA typing methods utilized by the Centres participating in the study, if available, are shown in Table 1.

| Country       | tTG kit      | EMA substrate | HLA typing kit |
|---------------|--------------|---------------|----------------|
| Albania       | Orgentec     | Monkey esophagus | NA             |
| Algeria       | Phadia - EliA Celikey | Monkey esophagus | NA             |
| Croatia       | Phadia - EliA Celikey | Monkey esophagus | Tepnel Lifecodes Corporation |
| Egypt         | Euroimmun    | NA            | NA             |
| Greece        | Inova        | Monkey esophagus | Olerup, HLA typing kits |
| Italy (ME)    | Euroimmun    | Umbilical cord | BioDiagene - DQ-CD Typing Plus kit |
| Italy (NA)    | Eurospital   | Monkey esophagus | BioDiagene - DQ-CD Typing Plus kit |
| Malta         | Orgentec     | Monkey esophagus | Invitrogen / Life technologies |
| Montenegro    | Aesku        | Monkey esophagus | Olerup, HLA typing kits |
| Morocco       | Orgentec     | Monkey esophagus | NA             |
| Slovenia      | Eurospital   | Monkey esophagus | Olerup, HLA typing kits |
| Spain         | Celikey; Pharmacia & Upjohn | Monkey esophagus | Tepnel Lifecodes Corporation |
| Tunisia       | Inova        | Monkey esophagus | NA             |
| Turkey        | Orgentec     | Monkey esophagus | Olerup, HLA typing kits |
With the exception of 1 centre, that utilized umbilical cord as substrate, all Centres assayed EMA on monkey esophagus as substrate. In each Centre at least 4 endoscopic biopsy samples from duodenum, including one from bulburs, were taken. Data provided by participants to the study were re-evaluated by A.S., L.G. and G.M, and classified as shown in Table 2. Crosstabs and stepwise statistics were generated by SPSS and t-Test, Relative Risk (RR) and Positive Predictive Value (PPV) were estimated for each variable assuming histology as the gold standard.

### Results

#### Population
Demographic data of all the patients, and according to the final diagnosis, are shown in Table 3. There were 1974 patients enrolled in the study, mean age 4 years, 10 months; 865 male, 1109 female. A global view of the classification and investigations performed by each Centre can be seen in the Flow Chart (Fig. 1) and in Table 4. CD was confirmed (CCD) in 511 (25.9%) and was unconfirmed (UCD) in 1391 (70.5%) patients. Apart from 14 patients diagnosed as having CD according to the new ESPGHAN guidelines (NCCD: New Criteria Celiac Disease), 2.47% of the final amount of diagnoses of CD, 43 patients were classified as having Potential Celiac Disease (PCD), 7.4% of the CD population, and 16 defined as having “high probability” of CD, as EMA or HLA were positive, but not both were done.

#### Symptoms
The proportion of asymptomatic cases enrolled for familiarity and of symptoms in CCD and UCD are shown in Table 5. A higher prevalence of asymptomatic cases, food refusal, globose abdomen and paleness was found in CCD, whereas abdominal pain and constipation were more common in the UCD. No difference was found for diarrhea and failure to thrive between the two groups.

### Diagnostic tools
Table 4 shows the frequency of various investigations performed in different countries: in 5 countries, HLA, and in one EMA assays were not available. HLA was not performed in Malta because it was not considered necessary.

#### Serology
In 91 patients, tTG antibodies were not performed; out of these, 7 patients showed positivity for EMA and histology, allowing to classify them as CCD, while in the other 84 cases CD was excluded (thus, they were classified as UCD, see Fig. 1). Of 1883 patients evaluated for tTG: 1219 were negative, while 664 were positive. Among the 1307 UCD patients in whom tTG were performed, 1215 resulted negative, while 92 resulted positive: 70/1307 (5.4%) had tTG titre higher than 2 x ULN, and 22/1307 (1.7%) had tTG titre higher than 10 x ULN. Four patients received diagnosis of CD despite having negative titre of tTG in presence of EMA positive: one was classified as PCD because of Marsh type 0, while the other 3 presented a Marsh type equal to or higher than 2. tTG sensitivity and specificity were 99.3% (95% CI 98.6-99.9) and 93% (95% CI 91.6-94.3) respectively, with a RR 1888.53 (95% CI 690.61-5164.35) of being celiac. Results of EMA assay are shown in Fig. 2. EMA sensitivity and specificity were 99.5% (95% CI 98.8-100%) and 90.1% (95% CI 87.5-92.7%) respectively.

Both EMA and tTG were performed in 464 patients who underwent intestinal biopsy as well: 66 were EMA negative and 398 EMA positive. The reliability of tTG versus EMA is defined by its sensitivity 95.7% (95% CI 93.86-97.54%) and specificity 95.8% (95% CI 93.91-97.69%). High titers of tTG > 10 x ULN were found in 427 patients, out of whom EMA were performed in 289 and were found absent in only 3 patients (1.04%). Intestinal biopsy was performed in 2 of these latter patients and in both, histology showed a Marsh type 3c confirming CD diagnosis. The third was classified as UCD because of having done neither HLA nor intestinal biopsy.

### Table 2 Classification of the patients’ diagnoses

| Classification            | Histology          | tTG               | EMA               | HLA               |
|---------------------------|--------------------|-------------------|-------------------|-------------------|
| CCDa                      | ≥ Marsh type 2     | Positive or not done | Positive or not done | Positive or not done |
| NCDD                      | Not done           | >10 x ULN         | Positive          | Positive          |
| UCD                       | Not done or Marsh type 0-1 | <5 x ULN | Negative          | Not done          |
| PCD                       | Marsh 0-1          | Positive          | Positive          | Positive          |
| High probability CDb      | Not done           | >10 x ULN         | Positive or not done | Positive or not done |

CD Celiac Disease, CCD Confirmed Celiac Disease, NCDD New Criteria Celiac Disease, UCD Unconfirmed Celiac Disease, PCD Potential Celiac Disease, tTG tissue transglutaminase type 2 antibodies, EMA endomysial antibodies, ULN Upper Limit of Normal

a at least tTG or EMA positive or both positive; bEMA or HLA positive but not both done. This category was not taken into account for comparison of the variables considered in the study.
In 135 patients with tTG > 10 x ULN, HLA genotyping was performed and in all of them it was compatible with CD.

Out of the 413 patients with tTG > 10 x ULN (excluding 14 patients diagnosed according to the new ESPGHAN criteria) both EMA and HLA were performed in 88. In all these patients a duodenal biopsy was performed, and in 85/88 the diagnosis would have been correctly made according to the new criteria; in 3 (3.41%) the diagnosis of PCD would have been missed in absence of the biopsy.

Biopsy was performed in 382 out of the 427 patients with high titre tTG, and histology showed at least a Marsh type 2 in 367 patients (96.1%). Thus, in this subgroup of patients, the positive predictive value of tTG > 10 x ULN was 96.1% (95% CI 94-97.9%).

Table 3 Demographic data according to the final diagnosis

| PATIENTS          | No. (%) | Gender (F/M) | Age (M ± SD) |
|-------------------|---------|--------------|--------------|
| Confirmed         | 511 (25.9%) | 320/191     | 4.1 ± 4.11   |
| Unconfirmed       | 1391 (70.5%) | 739/652     | 5.11 ± 4.89  |
| Potential         | 42 (2.1%)  | 28/14        | 4.25 ± 4.51  |
| Diagnosed according new ESPGHAN guidelines | 14 (0.7%) | 10/4 | 3.97 ± 3.59 |
| High probability  | 16 (0.8%)  | 12/4         | 2.98 ± 2.93  |

Out of 460 patients with Marsh type 0-1, 42 (9%) were classified as PCD in light of the positivity of EMA or tTG antibodies. In particular, 8 of them had tTG > 10 x ULN, 6 between 5 and 10 x ULN, 27 between 1 and 5 x ULN. One patient had a negative titre of tTG (0.9 x ULN), but he was symptomatic (abdominal pain) and had positive EMA with compatible HLA.

In 364/460 with a Marsh type 0-1 at biopsy, no antibodies were produced and they were classified as UCD.

Overall, 568 patients were diagnosed as having CD (including CCD, NCCD and PCD), 2.47% of whom according to the new guidelines.

The presence of high titre of tTG correlates with villous atrophy (Fig. 3).

HLA
Less than 20% (382) of the total number of enrolled patients underwent a HLA analysis: in 63, that were both DQ2 and DQ8 negative, CD was finally excluded they were classified as UCD.
**Associated diseases**

About 80% of the total study population had no other disease. The significant differences in prevalence of associated diseases in UCD and CCD are shown in Table 6. The frequency of thyroiditis, type 1 diabetes mellitus and dermatitis herpetiformis was higher in CCD, whereas IgA deficiency and hypertransaminasemia were higher in UCD.

**Discussion**

Our study, for the first time, provides a wide picture of CD diagnosis feasibility in 13 Mediterranean countries with different health resources and facilities. It is also the largest one investigating antibody diagnostics in paediatric CD that prospectively evaluates the new ESPGHAN criteria omitting biopsy.

In all participating countries, the diagnosis of CD relied on histology of duodenal biopsy, but other diagnostic procedures were not always available. In particular, in 5 countries, HLA, and in 1, EMA were not performed. Even though HLA was not required when the diagnosis was not in doubt, in some countries the limitation of performing it derives from its cost. The same is true for EMA assay.

On the other hand, in order to apply what is suggested by the new ESPGHAN guidelines, apart from the presence of symptoms and high antibody levels, HLA has to be compatible and EMA have to be present if the diagnosis of CD is to be made without a biopsy. In 4 centres, the diagnosis of CD was made for a total of 14 patients according to these new guidelines, omitting a duodenal biopsy.

Even though CD can be reliably diagnosed following the latest ESPGHAN and BSPGHAN guidelines [16], as not all diagnostic procedures required by the new guidelines are available in all countries, our results may suggest to further simplify the new ESPGHAN guidelines. As a matter of fact, it is not useful nor necessary to perform an expensive determination, such as HLA, as in all patients with tTG higher than 10 x ULN who had HLA heterodimer determined it was compatible with CD. Moreover EMA, which is not easily performed in all countries, does not add diagnostic accuracy to tTG, as

### Table 4 Distribution of patients by study centers and according to the final diagnosis and performed diagnostic investigations

| Country | N. Pts | N. CCD + NCCDa | N. UCD | N. PCD | N. tTG | N. EMA (in CCD) | N. Intestinal biopsy (in CCD) | N. HLA |
|---------|--------|----------------|--------|--------|--------|----------------|-------------------------------|--------|
| Albania | 45     | 25             | 20     | 0      | 45     | 7 (1)          | 32 (25)                       | 0      |
| Algeria | 71     | 17             | 54     | 0      | 70     | 6 (2)          | 54 (17)                       | 0      |
| Croatia | 310    | 12 + 1         | 293    | 3      | 304    | 25 (6)         | 202 (12)                      | 14     |
| Egypt   | 200    | 5              | 195    | 0      | 159    | 0              | 21 (5)                        | 0      |
| Greece  | 46     | 35             | 10     | 1      | 46     | 40 (31)        | 46 (35)                       | 27     |
| Italy (ME) | 332 | 111            | 199    | 15     | 307    | 273 (108)      | 142 (111)                     | 13     |
| Italy (NA) | 339 | 152 + 9        | 153    | 17     | 330    | 281 (151)      | 202 (152)                     | 109    |
| Malta   | 27     | 14             | 13     | 0      | 26     | 16 (14)        | 27 (14)                       | 0      |
| Montenegro | 18  | 11             | 4      | 2      | 17     | 5 (3)          | 16 (11)                       | 11     |
| Morocco | 106    | 45             | 61     | 0      | 100    | 1 (1)          | 90 (45)                       | 0      |
| Slovenia | 234 | 29 + 1         | 203    | 1      | 234    | 234 (29)       | 34 (29)                       | 66     |
| Spain   | 40     | 4 + 3          | 32     | 1      | 40     | 10 (4)         | 8 (4)                         | 9      |
| Tunisia | 67     | 22             | 44     | 1      | 66     | 23 (11)        | 43 (22)                       | 0      |
| Turkey  | 139    | 29             | 109    | 1      | 139    | 5 (1)          | 85 (29)                       | 133    |
| TOTAL   | 1974   | 511 + 14       | 1391   | 42     | 1883   | 926 (362)      | 1002 (511)                    | 382    |

N. Pts Number of Patients, N. CCD Number of Patients with Confirmed Celiac Disease, N. UCD Number of Patients with Unconfirmed Celiac Disease, N. PCD N. of Patients with potential celiac disease, N. tTG Number of tissue TransGlutaminase antibody assays, N. EMA Number of EndoMysial Antibody assays

*a*diagnosed according to new ESPGHAN criteria omitting biopsy

### Table 5 Distribution of symptoms in UCD and CCD patients

| Symptoms          | UCD (%) | CCD (%) | χ²  | p      |
|-------------------|---------|---------|-----|--------|
| No symptoms       | 93 (6.7%) | 120 (20.6%) | 82.4 | <0.0001 |
| Abdominal pain    | 402 (28.9%) | 69 (11.8%) | 65.9 | <0.0001 |
| Constipation      | 89 (6.4%) | 17 (2.9%) | 9.8  | 0.002  |
| Diarrhea          | 297 (21.4%) | 145 (24.9%) | 2.93 | 0.087  |
| Failure to thrive | 266 (19.1%) | 98 (16.8%) | 1.46 | 0.227  |
| Food refusal      | 16 (1.2%) | 14 (2.4%) | 4.3  | 0.038  |
| Globus abdominis  | 29 (2.1%) | 22 (3.8%) | 4.66 | 0.031  |
| Mood changes      | 5 (0.4%) | 6 (1%) | 3.33 | 0.068  |
| Paleness          | 46 (3.3%) | 31 (5.3%) | 4.43 | 0.035  |
| Vomiting          | 103 (7.4%) | 30 (5.1%) | 3.34 | 0.068  |
| Others            | 45 (3.2%) | 31 (5.3%) | 4.81 | 0.028  |

UCD Unconfirmed Celiac Disease, CCD Confirmed Celiac Disease
suggested by the cases in which both tests were performed and tTG was > 10 x ULN. In 3 cases of our study, in whom EMA were negative, histology showed a picture that allowed us to make the diagnosis of CD. Rather than determining EMA, in the presence of such a high titre tTG, it is better to repeat a second test for tTG according also to what is suggested by the Joint BSPGHAN and Coeliac UK guidelines for diagnosis and management of CD in children [17]. In a commentary regarding applicability of the new ESPGHAN guidelines for diagnosing celiac disease in children from resource limited countries [14], it has been suggested that positive HLA-DQ2/DQ8 serotype and EMA are necessary in order to apply the ESPGHAN guidelines for serological diagnosis of CD, and that CD should not be diagnosed on the basis of a single high tTG-titre. Our study comprising many countries with limited resources suggests that both HLA and EMA may be omitted and CD may be diagnosed on the basis of repeated high tTG titres. Altogether, the diagnosis would have been correctly made according to the new criteria in 85 out 88 patients with tTG > 10 x ULN who underwent tTG and EMA determination, together with intestinal biopsy. In 3 patients (3.41%), the diagnosis of PCD would have been missed in absence of the biopsy.
Thus, some practical issues need to be addressed. In adopting the new ESPGHAN criteria, it has to be kept in mind that there is a chance that patients might have a potential CD. In a prospective cohort study [18], which describes the long term natural history of potential CD by a 9 years follow-up, the risk of becoming atrophic was estimated at 18% especially in subjects with persistent positive serology, while serology became negative in 20% of potential patients on follow up. Even if rarely, potential celiac patients showed a TTG value >10 x ULN: hence this limit does not exclude the chance of finding potential celiac cases. Starting from this point, the decision to omit biopsy and the chance of being a potential CD should be thoroughly discussed with families considering the life-long diagnosis of CD. The new ESPGHAN guidelines also state that it is important to be precise in the clinical evaluation of patients and to perform prospective research studies. To the best of our knowledge, our prospective study is the largest one including 511 (+14) CD patients and 1391 controls and it shows that symptoms are not able to assign a pre-test probability to serological tests. On the other hand, Webb et al. [11] found no difference in terms of diagnostic accuracy of tTG in asymptomatic children diagnosed as having CD detected by screening.

We are aware of the limitations of our study, mostly due to the unequal distribution of enrolled patients across participating countries, although the total number is the largest one reported.

Therefore, further prospective multicentre studies with an homogeneous enrolment of patients should be planned also in order to try a further simplification of ESPGHAN guidelines.

Moreover, due to different test kinetics the 10 x UNL is not the same with all tTG tests. However, all the centres participating in the study utilized one of the 14 most frequently applied serum tTG assays in Europe taken in consideration in the new ESPGHAN guidelines Appendix. All these assays underwent United Kingdom National External Quality Assessment according to which the 10 x ULN was suggested by the new guidelines in order to omit intestinal biopsy. Considering that all the centres took at least 4 duodenal biopsy samples always including a sample from the bulbus we are confident that histology is the right gold standard chosen in this study.

### Conclusions

This is the largest prospective study providing a wide picture of CD diagnosis feasibility in Mediterranean countries with different health resources and facilities. The results of our study show that CD diagnosis still relies on intestinal biopsy in the Mediterranean area. New ESPGHAN criteria are not applicable in 5 countries due to lack of resources needed to perform HLA genotyping and, in one country, EMA assay. Further simplification of the new ESPGHAN guidelines might be made according to what preliminarily the present results suggest if confirmed by new prospective studies. This would be a result of great value especially for countries with limited resources, even though the chance of a potential CD has to be taken into account and discussed with the families when intestinal biopsy is omitted.

**Table 6** Significant differences in prevalence of associated diseases in unconfirmed celiac disease (UCD) and confirmed celiac disease (CCD)

| Associated diseases | UCD (%) | CCD (%) | $\chi^2$ | $p$ |
|---------------------|---------|---------|----------|-----|
| Thyroiditis         | 1       | 5.7     | 38.7     | 0.0001 |
| Type 1 Diabetes Mellitus | 7   | 3       | 16       | 0.0001 |
| Dermatitis herpetiformis | 0.1 | 1.5     | 17.1     | 0.0001 |
| IgA deficiency      | 1.8     | 0.3     | 6.3      | 0.012  |
| Hypertransaminasemia| 2.7     | 0.7     | 7.87     | 0.005  |

**Abbreviations**

- ESPGHAN: British society for pediatric gastroenterology, hepatology and nutrition; CCD: Confirmed celiac disease; CD: Celiac disease; ESPGHAN: European society for pediatric gastroenterology, hepatology and nutrition; NCCD: New criteria celiac disease; PCD: Potential celiac disease; PPV: Positive predictive value; RR: Relative risk; tTG: tissue transglutaminase type 2 antibodies; UCD: Unconfirmed celiac disease; ULN: Upper limit of normal

**Acknowledgement**

We thank Trays MacDonnell for revising the English of the article.

**Funding**

Italian Department of Health, Direction of International Affairs; Euromed action. Project: MEDICEL-Mediterranean Network for Celiac Disease – Phase II (CUP n° E61J11000450001); ELFID – European Laboratory for Food Induced Disease.

**Availability of data and materials**

Blinded data of patients were collected into a web-based database of the MEDICEL Mediterranean Network (www.medicel.unina.it/). Raw data are available upon request to the corresponding author.

**Authors’ contributions**

AS, LG and GM conceptualized and designed the study, carried out the initial analyses, drafted the initial manuscript, and approved the final manuscript as submitted. ZM drafted the initial manuscript, reviewed and revised the manuscript and approved the final manuscript as submitted. SC, DM-T, MA-Z, AK, AA, KB-N, MBH, ER, VV, MILT, TA and VD reviewed and revised the manuscript, and approved the final manuscript as submitted. All authors approved the final manuscript as submitted.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

The Ethics Committee of the University Hospital of Messina, where the Coordinating Centre is allocated, approved the study (Prot. E 35/12) and extended the approval to all the centers participating in the study according to the 2008, March 28th statement of the Italian Drug Agency (AIFA) on observational studies. Parent written consent was obtained in all the Centers participating in the study as suggested by ethical institutional review boards.
Authors’ information
Not applicable.

Author details
1Department of Translational Medical Sciences, School of Medicine, University “Federico II”, Naples, Italy. 2European Laboratory for Food-Induced Diseases, Naples, Italy. 3Children’s Hospital Zagreb, Zagreb, Croatia. 4Celiac Regional Centre, Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy. 5Paediatric Department, University Medical Centre, Maribor, Slovenia. 6Cairo University Children Hospital, El Cairo, Egypt. Department of Pediatric Gastroenterology, School of Medicine, Ankara University, Ankara, Turkey. 7Centre Hospitalier Universitaire Ibnou Rochd, Casablanca, Morocco. 8Faculté de Médecine d’Ouan, Ouan, Algeria. 9Pediatric Unit, Mongi SLUM’s Hospital of Tunis, Marsa, Tunisia. 10First Department of Pediatrics, University of Athens, Athens, Greece. 11Service of Pediatric Gastroenterology “Mother Teresa” Hospital, Tirana, Albania. 12Paediatric Gastroenterology Unit, Cruces University Hospital, Bilbao, Spain. 13University of Malta, Msida, Malta. 14Clinical Center of Montenegro, Podgorica, Montenegro.

Received: 6 June 2016 Accepted: 18 January 2017
Published online: 21 January 2017

References
1. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357:1731–43.
2. Greco L, Timponi L, Abkari A, Abu-Zeiky M, Attard T, Bouguerrâ F, Cullufi P, kansu A, Micetic-Turk D, Milak Z, Roma E, Shami R, Terzic S. Burden of celiac disease in the Mediterranean area. World J Gastroenterol. 2011;17:4971–8.
3. Emilsson L, Magnus MC, Størdal K. Perinatal risk factors for development of celiac disease in children, based on the prospective Norwegian Mother and Child Cohort Study. Clin Gastroenterol Hepatol. 2015;13:921–7.
4. Märdl K, Stephansson O, Montgomery S, Murray JA, Ludvigsson JF. Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort study. J Pediatr Gastroenterol Nutr. 2012;54:387–91.
5. Vriezinga SL, Auricchio R, Bravi E, Castillejo G, Chmielewska A, Crespo-Hernández M, Dübel AP, Kapoor S. Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with celiac disease. Indian J Gastroenterol. 2014;33:350–4.
6. Mårild K, Salminen J, Tuokko A, Vaasanen P, Lokki J, Laurila K, Collin P, Mäki M, Kaukinen K. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. J Pediatr Gastroenterol Nutr. 2012;54:387–91.
7. Kurppa K, Salminen J, Tuokko A, Saavalainen P, Löytynoja K, Laurila K, Collin P, Mäki M, Kaukinen K. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. J Pediatr Gastroenterol Nutr. 2012;54:387–91.
8. Paul SP, Mazhar H, Spray CH. Applicability of the New ESPGHAN Guidelines for Diagnosing Coeliac Disease in Children from Resource Limited Countries. J Coll Physicians Surg Pak. 2015;25:455–7.
9. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185–94.
10. Benelli E, Carato V, Martelossi S, Ronfani L, Not T, Ventura A. Coeliac disease in the ERA of the new ESPGHAN and BSPGHAN guidelines: a prospective cohort study. Arch Dis Child. 2016;101:172–6.
11. Murch S, Jenkins H, Auth M, Bremner R, Butt A, France S, Furman M, Gillett P, Kiparissi F, Lawson M, McLaren B, Sleet S, Sporle M, BSPGHAN. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of celiac disease in children. Arch Dis Child. 2013;98:806–11.
12. Auricchio R, Tosco A, Piccolo E, Galatola M, Izzo V, Maglio M, Paparo F, Troncone R, Greco L. Potential celiac children: 9-year follow-up on a gluten-containing diet. Am J Gastroenterol. 2014;109:913–21.
13. Webb C, Norström F, Måyllä A, Ivarsson A, Halvarsson B, Högborg L, Lagerqvist C, Rosén A, Sandström O, Stenhammar L, Carlsson A. Celiac disease can be predicted by high levels of anti-tissue transglutaminase antibodies in population-based screening. J Pediatr Gastroenterol Nutr. 2015;60:787–91.
14. Bhattacharya M, Lomash A, Sakhuja P, Dübel A, Kapoor S. Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with celiac disease. Indian J Gastroenterol. 2014;33:350–4.
15. Auricchio R, Tosco A, Piccolo E, Galatola M, Izzo V, Maglio M, Paparo F, Troncone R, Greco L. Potential celiac children: 9-year follow-up on a gluten-containing diet. Am J Gastroenterol. 2014;109:913–21.
16. Webb C, Norström F, Måyllä A, Ivarsson A, Halvarsson B, Högborg L, Lagerqvist C, Rosén A, Sandström O, Stenhammar L, Carlsson A. Celiac disease can be predicted by high levels of anti-tissue transglutaminase antibodies in population-based screening. J Pediatr Gastroenterol Nutr. 2015;60:787–91.
17. Bhattacharya M, Lomash A, Sakhuja P, Dübel A, Kapoor S. Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with celiac disease. Indian J Gastroenterol. 2014;33:350–4.
18. Auricchio R, Tosco A, Piccolo E, Galatola M, Izzo V, Maglio M, Paparo F, Troncone R, Greco L. Potential celiac children: 9-year follow-up on a gluten-containing diet. Am J Gastroenterol. 2014;109:913–21.

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit